Trospium chloride (cas 10405-02-4) is absorbed from two intestinal “absorption windows” with different permeability in healthy subjects
-
Add time:07/30/2019 Source:sciencedirect.com
Intestinal P-glycoprotein is regio-selectively expressed and is a high affinity, low capacity efflux carrier for the cationic, poorly permeable trospium. Organic cation transporter 1 (OCT1) provides lower affinity but higher capacity for trospium uptake. To evaluate regional intestinal permeability, absorption profiles after gastric infusion of Trospium chloride (cas 10405-02-4) (30 mg/250 ml = [I]2) for 6 h and after swallowing 30 mg immediate-release tablets in fasted and fed healthy subjects, were evaluated using an inverse Gaussian density function to model input rate and mean absorption time (MAT). Trospium chloride was slowly absorbed (MAT ∼10 h) after gastric infusion involving two processes with different input rates, peaking at about 3 h and 7 h. Input rates and MAT were influenced by dosage form and meal. In conclusion, trospium is absorbed from two “windows” located in the jejunum and cecum/ascending colon, whose uptake capacity might result from local abundance and functional interplay of P-glycoprotein and OCT1.
We also recommend Trading Suppliers and Manufacturers of Trospium chloride (cas 10405-02-4). Pls Click Website Link as below: cas 10405-02-4 suppliers
Prev:Unusual medium-chain polyunsaturated fatty acids from the snow alga Chloromonas brevispina
Next:Increasing dissolution of Trospium chloride (cas 10405-02-4) by co-crystallization with urea) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Effects of Tolterodine and Trospium chloride (cas 10405-02-4) on Renal Damage Induced by Partial Upper Urinary Tract Obstruction08/08/2019
- Effects of Combined Use of Trospium chloride (cas 10405-02-4) and Melatonin on In Vitro Contractility of Rat Urinary Bladder08/07/2019
- Lipid-based intravesical drug delivery systems with controlled release of Trospium chloride (cas 10405-02-4) for the urinary bladder08/06/2019
- Role of Trospium chloride (cas 10405-02-4) in Brachytherapy-Related Detrusor Overactivity08/05/2019
- Factors of adherence to treatment with trospium in employees08/04/2019
- Once Daily Trospium chloride (cas 10405-02-4) is Effective and Well Tolerated for the Treatment of Overactive Bladder: Results From a Multicenter Phase III Trial08/03/2019
- Extended-Release Trospium chloride (cas 10405-02-4) Improves Quality of Life in Overactive Bladder08/02/2019
- Trospium chloride (cas 10405-02-4) for overactive bladder may induce central nervous system adverse events08/01/2019
- Increasing dissolution of Trospium chloride (cas 10405-02-4) by co-crystallization with urea07/31/2019